103
Participants
Start Date
March 4, 2022
Primary Completion Date
July 31, 2024
Study Completion Date
July 31, 2024
BLU-451
BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
Carboplatin
Carboplatin will be administered intravenously (IV) on Day 1 of each cycle (every 3 weeks) for 4 to 6 cycles
Pemetrexed
Pemetrexed will be administered prior to carboplatin as an IV infusion on Day 1 of each cycle (every 3 weeks)
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Linkou Chang Gung Memorial Hospital (CGMHLK), Taoyuan District
Taichung Veterans General Hospital, Taichung
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York
Hospital of the University of Pennsylvania, Philadelphia
Georgetown University Medical Center, Washington D.C.
New Experimental Therapeutics of Virginia (NEXT Oncology), Fairfax
Northwestern Memorial Hospital, Chicago
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
Fred Hutchinson Cancer Center, Seattle
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
The University of Texas M.D. Anderson Cancer Center, Houston
Princess Margaret Cancer Centre, Toronto
National Cancer Center Hospital East, Kashiwa
Kanagawa Cancer Center, Yokohama
National Cancer Center Hospital, Chuo-ku
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Blueprint Medicines Corporation
INDUSTRY